MX376148B - Formulacion compuesta en capsula farmaceutica que comprende tadalafil y tamsulosina. - Google Patents
Formulacion compuesta en capsula farmaceutica que comprende tadalafil y tamsulosina.Info
- Publication number
- MX376148B MX376148B MX2015016995A MX2015016995A MX376148B MX 376148 B MX376148 B MX 376148B MX 2015016995 A MX2015016995 A MX 2015016995A MX 2015016995 A MX2015016995 A MX 2015016995A MX 376148 B MX376148 B MX 376148B
- Authority
- MX
- Mexico
- Prior art keywords
- tamsulosin
- tadalafil
- compound formula
- pharmaceutical capsule
- active ingredients
- Prior art date
Links
- 239000002775 capsule Substances 0.000 title abstract 3
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 title abstract 2
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 title abstract 2
- 229960000835 tadalafil Drugs 0.000 title abstract 2
- 229960002613 tamsulosin Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000002131 composite material Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se divulga una formulación compuesta en cápsula para prevenir o tratar la disfunción eréctil y la hiperplasia prostática benigna que comprende tadalafil y tamsulosina, y un método de preparación de la misma. La formulación compuesta en cápsula de la presente invención permite la separación completa de los dos ingredientes farmacéuticamente activos y reduce al mínimo la reactividad entre los ingredientes activos, y por lo tanto proporciona una excelente estabilidad del producto al paso del tiempo, aumentando al máximo así los efectos terapéuticos de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130076073 | 2013-06-28 | ||
| PCT/KR2014/005813 WO2014209087A1 (en) | 2013-06-28 | 2014-06-30 | Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015016995A MX2015016995A (es) | 2016-04-25 |
| MX376148B true MX376148B (es) | 2025-03-07 |
Family
ID=52142324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015016995A MX376148B (es) | 2013-06-28 | 2014-06-30 | Formulacion compuesta en capsula farmaceutica que comprende tadalafil y tamsulosina. |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3013327B1 (es) |
| KR (1) | KR102246657B1 (es) |
| CN (1) | CN105338970B (es) |
| AU (1) | AU2014299447B2 (es) |
| BR (1) | BR112015032728A2 (es) |
| EA (2) | EA033983B1 (es) |
| ES (1) | ES3028429T3 (es) |
| HK (1) | HK1219889A1 (es) |
| MX (1) | MX376148B (es) |
| PH (1) | PH12015502721B1 (es) |
| RU (1) | RU2672573C2 (es) |
| UA (1) | UA118110C2 (es) |
| WO (1) | WO2014209087A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391640B (es) * | 2015-01-28 | 2025-03-21 | Hanmi Pharmaceutical Co Ltd | Capsulas compuestas que comprenden raloxifeno y vitamina d o sus derivados. |
| KR20160100570A (ko) * | 2015-02-16 | 2016-08-24 | 한미약품 주식회사 | 탐수로신 염산염 함유 서방성 과립을 포함하는 경구용 약제학적 제제 |
| EA201891891A1 (ru) * | 2016-03-31 | 2019-04-30 | Ханми Фарм. Ко., Лтд. | Комбинированный препарат в виде капсулы, содержащий тадалафил и тамсулозин и обладающий улучшенной стабильностью и скоростью растворения |
| WO2017171483A1 (ko) * | 2016-03-31 | 2017-10-05 | 한미약품 주식회사 | 타다라필 및 암로디핀 함유 고형 복합제제 |
| KR101879133B1 (ko) * | 2017-07-11 | 2018-07-17 | (주)동구바이오제약 | 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법 |
| KR102169926B1 (ko) * | 2018-01-12 | 2020-10-26 | 주식회사 종근당 | 탐스로신과 타다라필을 포함하는 약제학적 조성물 |
| KR102805424B1 (ko) | 2019-12-23 | 2025-05-13 | 한미약품 주식회사 | 탐수로신 및 타다라필을 포함하는 경구용 복합제제 및 그 제조방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7670612B2 (en) * | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
| US20100221321A1 (en) * | 2003-02-27 | 2010-09-02 | Innercap Technologies, Inc. | Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions |
| KR100706036B1 (ko) | 2005-04-04 | 2007-04-11 | 대화제약 주식회사 | 염산 탐술로신 서방성 정제 및 그의 간단한 제조방법 |
| DE102005016981A1 (de) * | 2005-04-13 | 2006-10-19 | Bayer Healthcare Ag | Kombination zur Therapie bei benigner Prostatahyperplasie |
| KR100795419B1 (ko) * | 2006-01-03 | 2008-01-17 | (주)네오메딕스 | 암로디핀 및 아스피린을 함유하는 약학 제제 |
| EP2106792A1 (en) * | 2008-04-02 | 2009-10-07 | Pelvipharm | Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder |
| KR101861307B1 (ko) * | 2011-10-13 | 2018-07-06 | 한미약품 주식회사 | 정제를 포함하는 경질 캡슐 복합 제형 |
-
2014
- 2014-06-30 EA EA201690100A patent/EA033983B1/ru not_active IP Right Cessation
- 2014-06-30 BR BR112015032728A patent/BR112015032728A2/pt not_active Application Discontinuation
- 2014-06-30 RU RU2016102605A patent/RU2672573C2/ru active
- 2014-06-30 ES ES14817510T patent/ES3028429T3/es active Active
- 2014-06-30 EP EP14817510.2A patent/EP3013327B1/en active Active
- 2014-06-30 HK HK16107982.7A patent/HK1219889A1/zh unknown
- 2014-06-30 WO PCT/KR2014/005813 patent/WO2014209087A1/en not_active Ceased
- 2014-06-30 AU AU2014299447A patent/AU2014299447B2/en not_active Ceased
- 2014-06-30 CN CN201480036091.2A patent/CN105338970B/zh not_active Expired - Fee Related
- 2014-06-30 MX MX2015016995A patent/MX376148B/es active IP Right Grant
- 2014-06-30 EA EA201992020A patent/EA039091B1/ru unknown
- 2014-06-30 UA UAA201600633A patent/UA118110C2/uk unknown
- 2014-06-30 KR KR1020140081242A patent/KR102246657B1/ko active Active
-
2015
- 2015-12-07 PH PH12015502721A patent/PH12015502721B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12015502721A1 (en) | 2016-03-14 |
| KR102246657B1 (ko) | 2021-04-30 |
| EP3013327A1 (en) | 2016-05-04 |
| MX2015016995A (es) | 2016-04-25 |
| RU2016102605A3 (es) | 2018-05-15 |
| RU2672573C2 (ru) | 2018-11-16 |
| WO2014209087A1 (en) | 2014-12-31 |
| AU2014299447A1 (en) | 2015-12-17 |
| EP3013327B1 (en) | 2025-05-14 |
| ES3028429T3 (en) | 2025-06-19 |
| EA201690100A1 (ru) | 2016-04-29 |
| EA201992020A1 (ru) | 2020-01-16 |
| CN105338970A (zh) | 2016-02-17 |
| KR20150002550A (ko) | 2015-01-07 |
| RU2016102605A (ru) | 2017-08-02 |
| EA033983B1 (ru) | 2019-12-17 |
| EP3013327A4 (en) | 2016-11-16 |
| CN105338970B (zh) | 2019-07-09 |
| BR112015032728A2 (pt) | 2017-07-25 |
| PH12015502721B1 (en) | 2016-03-14 |
| HK1219889A1 (zh) | 2017-04-21 |
| AU2014299447B2 (en) | 2019-01-17 |
| EA039091B1 (ru) | 2021-12-02 |
| UA118110C2 (uk) | 2018-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX376148B (es) | Formulacion compuesta en capsula farmaceutica que comprende tadalafil y tamsulosina. | |
| MX2022001755A (es) | Compuestos de dinucleotidos ciclicos y metodos de uso. | |
| PH12018502251A1 (en) | Formulations of an lsd1 inhibitor | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| ZA201902053B (en) | Pharmaceutical composition | |
| PH12017500281A1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
| MX2017000026A (es) | Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| MX378435B (es) | Administración específica del sitio de un inhibidor de btk. | |
| HK1251481A1 (zh) | 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法 | |
| CY1124041T1 (el) | Συνθεσεις που περιλαμβανουν κυκλοσπορινη | |
| MX2017003561A (es) | Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos. | |
| IN2014MU00303A (es) | ||
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| NZ721780A (en) | Heterocyclic modulators of lipid synthesis for use against cancer and viral infections | |
| MX2018000546A (es) | Composiciones farmaceuticas que contienen celecoxib y tramadol. | |
| CR20160527A (es) | Derivados de carboxamida | |
| MX387731B (es) | Composiciones farmacéuticas orales de mesalazina. | |
| MY194081A (en) | Physiologically balanced injectable formulations of fosnetupitant | |
| TN2019000032A1 (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| PH12020500510A1 (en) | Prophylactic and/or therapeutic agent for diseases involving ido expression | |
| UA116499C2 (uk) | (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
| EA201891680A1 (ru) | Производные индана в качестве модуляторов mglur7 | |
| MX2021016053A (es) | Formulaciones de espuma rectal. | |
| GB2541348A (en) | Clopidogrel for use in the treatment of benign prostatic hyperplasia | |
| EA201691763A1 (ru) | Стабильная быстрорастворимая лекарственная форма, содержащая амоксициллин и клавулановую кислоту |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GD | Licence granted |